Journal
DIABETES CARE
Volume 36, Issue 8, Pages 2154-2161Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc12-2391
Keywords
-
Categories
Funding
- Janssen Research & Development, LLC
- Janssen Global Services, LLC
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- DVA
- Amylin Pharmaceuticals, Inc.
- AstraZeneca Pharmaceuticals LP
- Bristol-Myers Squibb Company
- Johnson Johnson
- Lilly Pharmaceuticals
- Novartis Pharmaceuticals Corporation
- Sanofi
- Daiichi-Sankyo, Inc.
- Novo Nordisk Pharmaceuticals, Inc.
Ask authors/readers for more resources
OBJECTIVECanagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption.RESEARCH DESIGN AND METHODSThis two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, H-3-glucose, C-14-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (RaO) in plasma, endogenous glucose production, and glucose disposal.RESULTSCompared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC(0-2h)] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE(0-6h), 18.2 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC RaO by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (approximate to 10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in RaO. Total glucose disposal over 0 to 6 h was similar across groups.CONCLUSIONSCanagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying RaO, likely due to intestinal SGLT1 inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available